Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_4
2
29%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 42 (40.0%)

Trials by Status

terminated114%
completed686%

Recent Activity

0 active trials
Showing 5 of 7
completed

Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

NCT01416194
completedphase_1

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

NCT02448771
completedphase_4

Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

NCT02602704
completed

Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)

NCT01470326
completedphase_4

Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women

NCT02090400
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01416194

Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

Completed
NCT02448771Phase 1

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Completed
NCT02602704Phase 4

Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

Completed
NCT01470326

Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)

Completed
NCT02090400Phase 4

Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women

Completed
NCT01634789Phase 1

A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women

Terminated
NCT00238745Phase 2

Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7